Skip to content
OpenCapital
Get started

Aquestive Therapeutics, Inc. AQST Current portion of mortgage and loans payable

Current portion of mortgage and loans payable at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$29.87M+102%

Other financials

Income statement

See full
Revenue$14.4M+65.7%
Gross profit$11.0M+117%
Operating income-$4.2M+78.3%
Net income-$8.1M+64.9%
EPS (diluted)-$0.07+70.8%

Balance sheet

See full
Cash & equivalents$110.7M+61.3%
Total debt$64.4M+7.4%
Total equity-$34.1M+44.1%
Total assets$141.1M+38.0%

Cash flow

See full
Operating cash flow-$14.8M+36.7%
CapEx$52.0K-61.5%
Free cash flow-$14.9M+36.9%

Valuation

See full
Market cap$560.13M+73.5%
Enterprise value$513.76M+63.6%
P/S11.1×+5.2×

Profitability

See full
Gross margin63.5%-4.9pp
Operating margin-111.2%+96.3pp
Net margin-137.1%+80.7pp
FCF margin-88.2%-2.2pp

Returns & leverage

See full
Return on equity145.1%—
Debt / equity-1.9×—
Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LoansPayableCurrent.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s current portion of mortgage and loans payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s current portion of mortgage and loans payable?
Aquestive Therapeutics, Inc. (AQST) reported current portion of mortgage and loans payable of $13.66M in Q1 2026.
How has Aquestive Therapeutics, Inc.'s current portion of mortgage and loans payable changed year-over-year?
Aquestive Therapeutics, Inc.'s current portion of mortgage and loans payable increased by 50496.3% year-over-year, from $27K to $13.66M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s current portion of mortgage and loans payable?
Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s current portion of mortgage and loans payable has grown at a 31.2% compound annual growth rate (CAGR), from $2.58M to $9.99M.